The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc Min/+ mice through activation of Wnt and ERK1/2 MAPK pathways

Oncogene

Volumn 29, Issue 32, 2010, Pages 4567-4575

  Wilson, C H ^a   McIntyre, R E ^a   Arends, M J ^b   Adams, D J ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cAMP; colorectal cancer; GNAS

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL LINEAGE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM; INTESTINE POLYP; MALE; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; UPREGULATION;

MUS;

EID: 77955655753     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.202     Document Type: Article

References (54)

1. Abud HE, Johnstone CN, Tebbutt NC, Heath JK. (2000). The murine A33 antigen is expressed at two distinct sites during development, the ICM of the blastocyst and the intestinal epithelium. Mech Dev 98: 111-114.
2. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M et al. (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63: 728-734.
3. Barbacid M. (1987). ras genes. Annu Rev Biochem 56: 779-827.
4. Bos JL. (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
5. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM et al. (2003). K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710.
6. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510.
7. Chen CJ, Liu JY, Cheng SN, Chang FW, Yuh YS. (2004). McCune-Albright syndrome associated with pituitary microadenoma: patient report. J Pediatr Endocrinol Metab 17: 365-369.
8. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA et al. (2003). Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 88: 4413-4417.
9. Conti M, Beavo J. (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
10. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C et al. (1993). Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75: 631-639.
11. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
12. Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC et al. (2003). Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hy-perplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 88: 2147-2151.
13. Fragoso MC, Latronico AC, Carvalho FM, Zerbini MC, Marcondes JA, Araujo LM et al. (1998). Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 83: 2074-2078.
14. Giles RH, van Es JH, Clevers H. (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24.
15. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN et al. (2008). Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600-608.
16. Happle R. (1986). The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 29: 321-324.
17. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A et al. (2001). Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 107: R31-R36.
18. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ et al. (2006). A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 38: 794-800.
19. Horvath A, Giatzakis C, Tsang K, Greene E, Osorio P, Boikos S et al. (2008). A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet 16: 1245-1253.
20. Houslay MD, Milligan G. (1997). Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22: 217-224.
21. Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE et al. (2000). Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 279: G500-G510.
22. Kalfa N, Lumbroso S, Boulle N, Guiter J, Soustelle L, Costa P et al. (2006). Activating mutations of Gsalpha in kidney cancer. J Urol 176: 891-895.
23. Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB. (1999). Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 134: 789-792.
24. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. (2000). Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26: 89-92.
25. Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G et al. (2009). Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 16: 565-572.
26. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. (1989). GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692-696.
27. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW. (1994). Inactivation of both APC alleles in human and mouse tumors. Cancer Res 54: 5953-5958.
28. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
29. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE et al. (2007). Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice. Oncogene 26: 4415-4427.
30. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE et al. (2009). Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 90: 558-574.
31. MacMahon HE. (1971). Albright's syndrome\thirty years later (polyostotic fibrous dysplasia). Pathol Annu 6: 81-146.
32. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
33. Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA. (2004). Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem 279: 26176-26183.
34. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A et al. (1991). Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253: 665-669.
35. Orner GA, Dashwood WM, Blum CA, Diaz GD, Li Q, Al-Fageeh M et al. (2002). Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat Res 506-507: 121-127.
36. Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, Rueda-Chimeno C, Barreiro-Morandeira F, Lado-Abeal J et al. (2008). Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Eur J Endocrinol 159: 623-631.
37. Plagge A, Kelsey G, Germain-Lee EL. (2008). Physiological functions of the imprinted Gnas locus and its protein variants Galpha(s) and XLalpha(s) in human and mouse. J Endocrinol 196: 193-214.
38. Radtke F, Clevers H. (2005). Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904-1909.
39. Rudolph JA, Poccia JL, Cohen MB. (2004). Cyclic AMP activation of the extracellular signal-regulated kinases 1 and 2: implications for intestinal cell survival through the transient inhibition of apoptosis. J Biol Chem 279: 14828-14834.
40. Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V et al. (2006). Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci USA 103: 14122-14127.
41. Sieber OM, Tomlinson IP, Lamlum H. (2000). The adenomatous polyposis coli (APC) tumour suppressor\genetics, function and disease. Mol Med Today 6: 462-469.
42. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
43. Stork PJ, Schmitt JM. (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266.
44. Stratakis CA. (2003). Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab 14: 404-410.
45. Su H, Mills AA, Wang X, Bradley A. (2002). A targeted X-linked CMV-Cre line. Genesis 32: 187-188.
46. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C et al. (1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670.
47. Taboada GF, Tabet AL, Naves LA, de Carvalho DP, Gadelha MR. (2009). Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience. Pituitary 12: 165-169.
48. Taketo MM. (2006). Mouse models of gastrointestinal tumors. Cancer Sci 97: 355-361.
49. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. (2004). Minireview: GNAS: normal and abnormal functions. Endocrinology 145: 5459-5464.
50. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. (1991). Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325: 1688-1695.
51. Wilkins JA, Sansom OJ. (2008). C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 68: 4963-4966.
52. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
53. Yang GC, Yao JL, Feiner HD, Roses DF, Kumar A, Mulder JE. (1999). Lipid-rich follicular carcinoma of the thyroid in a patient with McCune-Albright syndrome. Mod Pathol 12: 969-973.
54. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al. (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667.